WSJ : Adyen’s IPO Success Spurs Hopes European Tech Scene Has Turned a Corner

Adyen’s IPO Success Spurs Hopes European Tech Scene Has Turned a Corner
London, Paris and Berlin have developed tech ecosystems, with growing numbers of local venture-capital firms and incubators

The rousing recent listing of Dutch payments company Adyen ADYEN -5.38% NV is offering investors hope that Europe’s tech scene is finally fertile enough to generate a stream of successful startups.

Adyen, which handles payment-processing for blue chips including Netflix Inc., Facebook Inc. and Uber Technologies Inc., has sparked excitement following its initial public offering in June—one of Europe’s largest this year. Its shares are up 156% since the IPO, valuing the company at more than $25 billion.

Investors view Adyen, founded in 2006 and profitable since 2011, as a less-expensive way to tap into the growth of its better known clients, which also include old-economy retailers. For startup boosters across Europe, its success is evidence of maturing among both tech firms and their local business environments.

The trend differs from past excitement about the European tech scene, which had its share of false starts over the past two decades. The number and variety of startups has ballooned in recent years, and they attract a growing amount of venture capital.

In the first half of 2018, European venture-backed startups attracted $8.7 billion in equity financing, up 13% from the same period a year earlier and up 44% from five years ago, according to Dow Jones VentureSource. This compares with $34 billion in the U.S. over the same period, showing how wide the gap between Europe and Silicon Valley remains.

The Adyen IPO “serves as a role model for other entrepreneurs at high-growth tech companies,” said Constantijn van Oranje, special envoy for Dutch tech-entrepreneurship promotion office StartupDelta and a younger brother of Dutch King Willem-Alexander.

Marili ‘t Hooft-Bolle, chief operating officer at cloud-storage firm WeTransfer, said Adyen’s offering proves there is “more willingness from the capital side to invest in Europe as whole.”

Adyen was launched by two entrepreneurs who previously built and cashed out of a fintech startup. They are among a growing European wave of serial tech founders who are tapping experience, connections and capital from earlier ventures to establish and finance new ventures.

“There are more examples in the market of how you can do it,” said Adyen co-founder and chief executive Pieter van der Does. “We started from another startup.”

London, Paris and Berlin already have developed tech ecosystems, with growing numbers of local venture-capital firms and incubators, as well as successful launches.

London has a slew of fintech firms like Revolut Ltd. and Funding Circle Holdings Ltd., which plans an IPO next month; Paris has established firms like carpooling service BlaBlaCar and a mammoth new startup campus called Station F; and in Berlin, startup factory Rocket Internet RKET -4.50% SE has spawned several ventures that have gone public in recent years, including Zalando ZAL -0.12% SE, Delivery Hero AG DHER -0.93% and HelloFresh SE.

Other European cities are aiming to replicate that formula. Stockholm got a boost from the success of music-streaming service Spotify Technologies SA and now other Swedish successes are finding exits, like payments firm iZettle, which was bought earlier this year by PayPal Inc. just before it was going to go public. The Estonian creators of Skype have helped promote Tallinn as a tech hub with successes like fintech startup TransferWise Ltd.

“You’re now seeing the components come together in a really broad range of cities across the region,” said Tom Wehmeier, a partner at London-based investment firm Atomico.

Natalie Novick, an American sociologist who studies European startup ecosystems, has found that 21% of European tech entrepreneurs started their companies outside their home countries. Berlin, she notes, is unusual by German standards in tolerating business failure. In France, initiatives such as changes to capital-gains rules for startup founders and visas for foreign entrepreneurs—some launched almost a decade ago and given new energy by President Emmanuel Macron—have cut red tape and boosted enthusiasm around entrepreneurship.

But while Europe’s cadre of veteran entrepreneurs with time and experience to share is growing, it remains far smaller than Silicon Valley’s.

“There’s just not that big a community of people who’ve cashed out and are able to give back,” said Robert Vis, founder and CEO of MessageBird, which helps companies including Uber and Domino’s Pizza communicate with customers.

“To win, you have to create an ecosystem where everyone is willing to give something without getting something in return.”

FT : Property speculators head north as London market slumps

Property speculators head north as London market slumps
Rising house prices encourage ‘flippers’ to look outside capital

UK property speculators who buy and sell homes in quick succession have shifted their focus north as the housing market in London and the south-east begins to slump.

Some 11 of the top 15 destinations for “flipping” homes — buying and selling within 12 months — were in the north of England last year. None of the top 15 were in the capital, in contrast with preceding years.

House price growth in London slowed almost to a standstill in 2017, and moved into negative territory this summer.

But in the regions house prices are rising. The top destination for “flipping” was Burnley in Lancashire, where more than 6 per cent of all homes sold in the year were rapidly sold again, according to an analysis of Land Registry data by Hamptons International, a division of Countrywide.

Burnley remains the cheapest local authority in England in which to buy a home: the average property costs £81,352.

But a less buoyant nationwide market offered speculators fewer opportunities for a quick profit and they reduced the total sum they committed.to houses for rapid sale.

Some £4.1bn worth of homes were sold at least twice in a year in England and Wales in 2017, down £200m from the previous year.

A stamp duty surcharge of 3 per cent of the price of second and additional homes, introduced in April 2016, has also discouraged some speculators, said Aneisha Beveridge, research analyst at Hamptons.

“Some northern areas are more resilient. Lower property prices mean that some of the homes bought by flippers fall under the £125,000 stamp duty threshold,” she added.

The analysts found that 18,085 homes, or 2 per cent of all residential properties that changed hands in England and Wales in 2017, were sold again within a year. Buyers who “flip” homes seek to take advantage of rapid house price growth, though they may also carry out some improvements to the property.

The most popular destinations after Burnley were Middlesbrough, Redcar and Cleveland, and County Durham.

By contrast, three years earlier, the top 15 destinations included Kensington and Chelsea, London’s most expensive borough, where runaway house price growth combined with already high prices to create easy profits for speculators.

The average home there now costs £1.2m, even after an annual drop in prices of almost 14 per cent.

“Price growth in the north will continue to outpace prices in the south, as these are the areas worst affected by affordability pressures,” Ms Beveridge said.

Levels of property speculation since the financial crisis have not equalled those of the early 2000s, when a 13 per cent annual rate of house price growth resulted in more than £6bn of “flipping” annually for six consecutive years.

Barron's : ObsEva: A Small Biotech With a Promising Pipeline

ObsEva: A Small Biotech With a Promising Pipeline

A small Swiss biotech company focused on women’s reproductive health has three promising treatments reaching key development stages in the next few months that could pay off for investors.

Shares of Geneva-based ObsEva (ticker: OBSV) have already rallied from a low of $5.13 in June 2017 to $14.86, but the company boasts a number of potential products, and allure as a possible takeover target, that could propel the price higher.

One challenge is ObsEva’s European location, which some investors find unattractive. The region’s slow growth and banking worries have led some to dismiss all stocks there, even those seemingly unaffected by the issues. “This is a great, exciting, dynamic, global company sitting in the wrong ZIP Code,” says Adam Johnson, founder of the Bullseye Brief newsletter. But he suggests that ObsEva’s appeal extends much further: “The fact that the company sits in Geneva has no impact on its ability to help women across the globe.”

Founded in 2012, ObsEva specializes in drug therapies for reproductive problems. These include Linzagolix, a medicine to treat both uterine fibroids (or cysts) and endometriosis (which often produces painful uterine bleeding). Plus, there is Nolasiban, designed to improve the success of in vitro fertilization, and OBE022, a therapy to help prevent the early onset of labor.

Currently, the drugs are in various stages of clinical approval in the U.S. and Europe, with the results expected relatively soon. Data on U.S. Food and Drug Administration and European Union Phase 2 and 3 trials for Linzagolix will be released by the end of 2018, and late 2019, respectively. By year-end, investors can expect Phase 3 trial results for Nolasiban and Phase 2 data on OBE022. If a medication is successful in Phase 3 trials, that’s usually the final stage before its wide distribution.

“These are important catalysts related to significant data on Linzagolix and Nolasiban,” a company spokesman says, referring to likely forthcoming results. “In principle, it is further validation of the previous clinical data and patient benefits.” Already, ObsEva’s products have shown effectiveness in the clinic. “[Linzagolix] proved three times more effective at reducing bleeding in patients suffering from uterine fibroids compared to the placebo,” claims a recent Bullseye Brief.

Such data help build investor confidence.

“We believe that at current levels, the stock does not fully reflect the commercial potential of its lead product, Linzagolix,” says a recent report from Leerink Partners, a Boston-based investment bank specializing in health-care companies. It sees the possibility of more than $1 billion in peak annual sales for that drug and as much as $165 million annually for Nolasiban. Trial data for the latter show significant improvement in pregnancy rates “and may even be sufficient for approval in [the European Union],” says Leerink, which values the stock at $25.

ObsEva CEO Ernest Loumaye has a solid track record. He founded PregLem, another drug company dedicated to products for women and based in Geneva, in 2006 with $75 million in venture-capital money. In 2010, Hungarian multinational drugmaker Gedeon Ritcher acquired PregLem for some $500 million.

“We have never talked so much about women’s rights, and yet most of the pharma industry has left women’s health to focus on other things,” Loumaye tells Barron’s. Nolasiban and OBE022 were each developed by other firms, which then shelved further work on them, he says. Both have no pending competition, he contends. Linzagolix is delivered via a single daily dose, doesn’t react with food or other pharmaceuticals, and doesn’t require patients to take hormone therapy.

Investors must understand that buying ObsEva is risky. It’s tiny, with a market capitalization around $675 million. In addition, losses hit $1.03 a share in the six months through June, and investors expect them to total $2.03 for 2019. The potential for regulatory approval hiccups could delay future revenue.

Given the uncertainty, estimates of its stock’s true value vary widely, from $24 to $44, according to Yahoo! Finance. Many assumptions are required to generate a valuation, including potential market size and how much of it a drug will penetrate, how quickly the product will come to market, and how it will be priced. Small differences in any assumption would mean huge valuation changes.

However, there’s a back-of-the envelope calculation that Bullseye Brief’s Johnson uses to estimate the shares’ potential. If the data from the trials prove to be positive, the stock could jump by as much as 50%, and if a major pharmaceutical company purchases ObsEva, expect another 50% premium, he says. That would mean $30 a share, double its current level.

Barron's :‘We’re Using the Future for a Fiscal Dumping Ground.’ Beware Trillion-

‘We’re Using the Future for a Fiscal Dumping Ground.’ Beware Trillion-Dollar Deficits

There’s no snooze button on the national debt clock, though you wouldn’t know it by the way public alarm has quieted as the situation grows worse.
October begins a new fiscal year for the U.S. government—and a faster ballooning of how much it owes. Barring a behavioral miracle in Congress, trillion dollar yearly budget shortfalls will return, perhaps as soon as the coming year. And unlike the ones brought by the
financial crisis and Great Recession of 2007-09, these will start during a period of relative plenty, and won’t end.
Debt held by the public, a conservative tally of what America owes, will swell from $15.7 trillion at the end of September, or 78% of gross domestic product, to $28.7 trillion in a decade, or 96% of GDP.
Those estimates, provided by the Congressional Budget Office, are based on reasonable assumptions about economic growth, inflation, employment, and interest rates, but they leave out some important things. They assume that the nation’s need for increased infrastructure investment, estimated by the American Society of Civil Engineers at $1.4 trillion through 2025, goes unmet. They don’t account for the possibility of another financial crisis, or war, or a rise in the frequency or severity of natural disasters, and they assume that some Trump tax cuts will expire in 2025.
There is no clear milestone that marks the moment a country loses control of its finances, but consider how the bar has already been lowered for what seems possible in Congress. Even debt scolds no longer talk seriously about America paying down what it owes, or holding the dollar amount steady. The new path of fiscal prudence involves containing debt at some manageable percentage of GDP, and the opportunity for that is slipping.


“It’s a generational issue,” says Robert Bixby, executive director of the Concord Coalition, a nonpartisan group focused on the debt. “We’re using the future for a fiscal dumping ground.” Another view of the national debt can be found here.
Just holding the line at 78% of GDP over the next three decades would require finding massive, immediate savings in the budget—$400 billion over the coming year, rising gradually to $690 billion by 2048, using 2019 dollars. In comparison, America spent $590 billion in fiscal 2017 on defense, and $610 billion on all other discretionary items. (The rest of the $4 trillion in spending went for mandatory programs, such as Social Security and Medicare, and for interest on the debt.)
This past week didn’t inspire confidence. House Republicans introduced Tax Cuts 2.0—bills touted as “permanent tax relief for families and small businesses.” But a fresh decline in federal revenue and the resulting increase in the deficit will hardly come as relief to the taxpayer whose share of the national debt, now $164,000 on average, is already set to top $250,000 in a decade. The 2.0 round has little chance in the Senate, and appears mostly designed to force Democrats into voting against “relief” ahead of midterm elections. Investment bank UBS forecasts a 60% likelihood that Democrats will take the House in November, with Republicans keeping the Senate, the most likely result of which will be gridlock. Here’s hoping a mixed Congress can get something done, because even now, there remain plausible paths to fiscal reform.

Both Sen. Mike Enzi (R., Wyo.), chairman of the Senate Committee on the Budget, and Rep. Steve Womack (R., Ark.), chairman of the House Budget Committee, declined to talk with Barron’s about the debt.
This is no panicked warning for stock and bond investors, because the chances of a debt-driven blowup appear low in the near term. In fact, the biggest risk related to markets is that placid conditions will add to complacency. With the 10-year Treasury yield near 3%—around half its average of the past half-century—it’s clear that there remain eager buyers for America’s debt.
The problem is that we could be wrong about the limited investment risk. “I don’t think bonds adequately reflect what at some point in the future, with high probability, will be trouble in bond markets and with interest rates, due to our fiscal situation,” says Robert Rubin. Treasury Secretary from 1995 until mid-1999 in the Clinton administration, he was one of the last in that position to oversee budget surpluses. Rubin points out that Greek government bond yields were modest for years before spiking past 25% in 2012, during a debt crisis.
If the party that has long branded itself as fiscally conservative—and showed off a debt clock during the 2012 Republican National Convention, in a call to action—now has little interest in containing deficits during good times, the result could be a costly backlash during the next bust. Bond guru Jeffrey Gundlach oversees more than $120 billion in investor assets as chief investment officer at DoubleLine Capital, and was early to predict Donald Trump’s election win and the shift to faster debt growth. He has called the act of expanding deficits while the Federal Reserve is raising interest rates a “suicide mission.”

Gundlach expects investors to buy Treasuries if the threat of deflation returns “as a Pavlovian reaction” and notes that a high short position in them could even set up a short squeeze. “After that, you might find yourself with a more radical reaction,” he says. “There could be elevated acceptance of a universal basic income—just send everyone money.” Already, there is a movement afoot among a small group of economists on the left who point out that governments that borrow in money they print can’t technically go bankrupt, and say that budget deficits are, if anything, too small.
When deficits are large, money tends to be spent on “stupid things,” says Maya MacGuineas, president of the nonpartisan Committee for a Responsible Federal Budget. “If you don’t have constraints, you don’t think about how to spend wisely.” MacGuineas calls the debt “the most predictable crisis we’ve ever faced,” but says spotting the tipping point will be difficult, because much depends on other countries, and their appetite for our debt. “We can borrow a lot more if we’re still the best-looking horse in the glue factory,” she says.
The gross national debt, a figure commonly used for debt clocks, topped $21 trillion in March. We focus here on debt held by the public, which subtracts amounts owed by one part of the government to another, such as Treasuries held in the Social Security trust fund. The debt is what we owe. The deficit is the amount by which we go further into the hole each year.
Not all deficits are bad. The $1 trillion-plus deficits America ran for four years ending in 2012 helped shore up its financial system and prevent a deep recession from turning into a prolonged depression. Keynesian economics calls for deficit spending and lower taxes during economic slumps to stimulate demand, with the money recouped through surpluses during good years. That last part isn’t happening, however. “Now Keynesian seems to mean you stimulate all the time,” says Gundlach.
If the debt were growing more slowly than the economy—or put differently, with the deficit projected to total 4.6% of gross domestic product over the next year, if GDP were climbing faster than 4.6% in nominal terms—the burden could be said to be slowly diminishing. As it turns out, the economy is estimated to have risen faster than that on an annualized basis last quarter, but it got a boost from temporary factors, including a rush by America’s trading partners to stock up on goods ahead of new tariffs.

Over the coming 10 fiscal years, the CBO estimates real annual GDP growth averaging about 1.7%, and nominal growth of 4.0%. Deficits, meanwhile, are expected to rise from here, averaging 4.9% of gross domestic product annually over the coming decade. The projected downshift in economic expansion owes in part to a widely accepted demographic challenge: the ongoing retirement of the baby boomers, which will hold back expansion of the labor force, a key determinant of GDP gains.
A few commonly prescribed fiscal remedies won’t, on their own, do the job: cutting foreign aid; cracking down on waste, fraud and abuse; and reining in welfare. Foreign aid, using a broad definition that includes things like military assistance to fight terrorism, is around $50 billion a year—a sliver of needed savings. Waste, fraud and abuse are surely all lurking in the budget, but the Government Accountability Office puts improper payments for all federal entities at $141 billion in fiscal 2017, and the challenge is driving that figure lower without spending mightily on new compliance efforts. Consider welfare a catchall term for means-tested programs that are part of mandatory spending, like Medicaid; the earned-income tax credit; and the Supplemental Nutrition Assistance Program, sometimes still referred to as food stamps. Then the combined dollar amount is significant—an estimated $742 billion this fiscal year. But it is dwarfed by the $2.1 trillion that will be spent on mandatory programs that aren’t means-tested, like Social Security, military retirement programs, and most of Medicare.
TELL US WHAT YOU THINK
Should we care about the growing deficit and total debt? Write us at mail@barrons.com and we may publish your take. Find out more at barrons.com/mailbag.
“There’s no low-hanging fruit, politically,” says Concord Coalition’s Bixby. “It’s the entitlement programs, and the baby boomers have already begun to collect.” The boomers are sometimes described as a metaphorical pig in a python, but Bixby points out that while Social Security’s deteriorating fiscal condition could stabilize after the boomers retire, it will not reverse, and that Medicare’s challenges will keep growing. “It’s more like a telephone pole in a python,” he says.
Like Bixby, former Treasury Secretary Rubin points to cutting Medicare cost growth and raising federal revenue as jobs 1 and 2 in fixing the deficit. “You need comprehensive health-care reform that is focused on costs,” says Rubin. “If you can reduce cost growth in Medicare and Medicaid, even without cutting entitlements, you’re halfway there,” he says. The other half is revenue. During the last, brief flirtation with budget surpluses, from 1998 through 2001, yearly federal receipts were 19% to 20% of GDP. Over the next several years, that figure is expected to bottom at 16.4% before beginning to rebound—if certain tax cuts expire.
There is little consensus around the theory that deficit-fueled tax cuts goose growth enough to pay for themselves over time. But there is every reason to believe that fiscal reform will be good for growth, as interest costs are contained and private investment takes the place of government borrowing. Even under the scenario of merely holding the debt to 78% of GDP for the next 30 years, the CBO estimates that gross national product per person would end up 4.5%—or about $4,100—higher, compared with baseline assumptions.
The last bold effort to deal with the debt was the Simpson-Bowles plan drafted by a bipartisan commission appointed by President Obama in 2010, when debt was 61% of GDP. It called for nearly $4 trillion in deficit reductions through 2020, with big cuts to discretionary spending, changes for Social Security and Medicare, and a lowering of personal and corporate tax rates, combined with purging the tax code of breaks. That would have put debt on a course toward an estimated 40% of gross domestic product by 2035. The final draft, titled “The Moment of Truth,” didn’t win enough support to come to a vote in Congress.
Dwindling Choices
A breakdown of government outlays shows that a shrinking portion of spending comes from discretionary programs.

The last big fiscal success, the “Clinton surpluses” of 1998-2001, can be traced in part to the efforts of President George H.W. Bush. He was faced with a dangerous combination of a weakening economy and high interest rates. To convince the Federal Reserve to lower rates, he needed smaller budget deficits. A Democratic Congress wouldn’t agree to spending cuts without higher tax revenue. But Bush had famously promised, “Read my lips, no new taxes” during the 1988 Republican Convention. In the end, he reached a bipartisan deal that included about $2 in spending cuts for each $1 in added revenues, including from a tax hike on high earners. That deal helped cost Bush re-election in 1992. President Clinton followed up with a deficit-cutting budget in 1993.
The deficit fell from 4.5% of gross domestic product in 1992 to near-breakeven five years later, before swinging to surpluses. The lesson of what might rightly be called the Bush-Clinton surpluses is that budget reform isn’t a job for narcissists or glory seekers, because the public outrage forms immediately, and the benefits don’t become clear until much later, by which time others will have arrived to help collect the high-fives.
The good news is that, if the courage to tackle the deficit somehow visits Capitol Hill, financial markets appear likely to cooperate, at least for a while.
In a recent analysis, economists at J.P. Morgan studied historical debt defaults, bailouts and inflation spikes since World War II in countries that resemble the U.S. economically. They found that the probability of these things occurring within any five-year period was less than 6%. Statistically, the link between debt levels and crises is surprisingly weak. That is, crises have occurred in countries with lower debt/GDP than the U.S. has now, and some countries with higher debt/GDP have avoided crises. Many crises corresponded with specific currency problems that, for the U.S., seem less relevant.

>>> US Close Dow +0,03% S&P +0,03% Nasdaq -0,05% Russell +0,43%


Closing Market Summary: Upbeat Week Ends on Flat Note

The stock market saw limited movement on Friday, ending a positive week on a flat note. The S&P 500 (unch) settled just above its flat line, locking in a 1.2% gain for the week. The Dow (unch) and Nasdaq (-0.1%) also finished near their flat lines, ending the week with respective gains of 0.9% and 1.4%.

Equities started the day just above yesterday's closing levels, but relative weakness in a handful of rate-sensitive sectors and a mixed showing from other groups kept the market near its unchanged level. The underperformance in groups like utilities (-0.5%), telecom services (-0.4%), and real estate (-0.9%) was owed to overnight and early-morning selling in Treasury futures, which lifted the 10-yr yield to a six-week high just below the 3.000% area.

The broader market treaded water during early trade, thanks to gains in cyclical sectors like financials (+0.7%), industrials (+0.5%), and energy (+0.6%). The S&P 500 was on the verge of climbing to a fresh high around noon, but a Bloomberg report, indicating that President Trump is seeking to impose tariffs on $200 billion worth of imports from China despite the recent efforts to revive trade talks, sent the broader market to a session low.

In addition to pressuring stocks, the news weighed on offshore yuan and helped the U.S. Dollar Index (94.94, +0.42) climb to a fresh high, trimming this week's loss to 0.4%.

Afternoon trade saw a slow climb off session lows, but the S&P 500 was not able to revisit its high, as heavily-weighted groups like consumer discretionary (-0.3%) and health care (-0.3%) struggled. For its part, the top-weighted technology sector spent the session near its flat line, ending little changed.

The market received just two earnings reports between yesterday's closing bell and today's open. Adobe Systems (ADBE 274.69, +6.17) climbed 2.3% to a fresh record after beating earnings and revenue expectations while Dave & Buster's (PLAY 62.05, +4.53) rose 7.9% to a 13-month high after beating quarterly expectations and initiating a quarterly dividend of $0.15 per share.

Treasuries ended the day with losses, though intraday action saw the complex climb off mid-morning lows. The 10-yr yield rose three basis points to 2.99% after approaching its August high (3.02%) in early trade.

Investor participation was fairly consistent with the past two sessions as 762 million shares changed hands at the floor of the New York Stock Exchange.

Participants received a sizable batch of economic data today, including August Retail Sales, August Import/Export Prices, August Industrial Production and Capacity Utilization, July Business Inventories, and the preliminary reading of the University of Michigan Consumer Sentiment Index for September:

  • August retail sales rose 0.1% (consensus +0.4%), while the July increase was revised to 0.7% from 0.5%. Excluding autos, retail sales increased 0.3% in August (consensus +0.5%), and the July increase was revised to 0.9% from 0.6%.
    • The upward revisions to the prior month helped mitigate some of the headline disappointment for August, yet the key takeaway from the report is that consumer spending is up and will continue to support real GDP growth in the third quarter.
  • Import prices declined 0.6% in August after sliding a revised 0.1% in July (from 0.0%). Excluding oil, import prices slid 0.1% in August after slipping an unrevised 0.3% in July.
    • The key takeaway from the report is the recognition that nonfuel import prices have declined for three straight months, underscoring perhaps some of the effects of a stronger dollar. The moderation in nonfuel import prices could help temper budding inflation concerns for the time being.
  • Industrial Production rose 0.4% in August (consensus +0.4%), while the July increase was revised to 0.4% (from 0.1%). Meanwhile, Capacity Utilization came in at 78.1% (consensus 78.3%), up from a revised reading of 77.9% in July (from 78.1%).
    • The key takeaway from the report is the understanding that factory output was unchanged, excluding the gain in motor vehicles and parts.
  • Business Inventories rose 0.6% in July (consensus +0.6%). The June reading was left unrevised at +0.1%.
    • The key takeaway from the report is that business sales continued to outpace inventory growth year-over-year, which is a favorable trend that carries the potential to lead to a better pricing environment for businesses.
  • The preliminary reading of the University of Michigan Consumer Sentiment Index for September rose to 100.8 (consensus 97.0) from 96.2 in August.
    • The key takeaway from the report is that the pickup in sentiment was widespread across all major socioeconomic groups, which is a good underpinning for solid consumer spending activity.

Monday's economic data will be limited to the 8:30 ET release of the Empire Manufacturing report for September (consensus 23.0).

  • Nasdaq Composite +16.0% YTD
  • Russell 2000 +12.2% YTD
  • S&P 500 +8.7% YTD
  • Dow Jones Industrial Average +5.8% YTD